Finance
2025.09.19
Lumosa Submits LT3001 Phase 3 Trial Consultation to the US FDA
September 19, 2025 – Lumosa Therapeutics (TPEx: 6535) has submitted a consultation request to the U.S. FDA regarding the Phase 3 clinical trial of LT3001. The submission includes the trial design overview and regulatory requirements for potential market approval. The FDA will provide guidance following its review.
